Surgical Considerations in Portal Hypertension.
Cirrhosis
Hepatic management
Liver resection
Malignancy
Outcome
Portal hypertension
Journal
Clinics in liver disease
ISSN: 1557-8224
Titre abrégé: Clin Liver Dis
Pays: United States
ID NLM: 9710002
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
medline:
1
7
2024
pubmed:
1
7
2024
entrez:
30
6
2024
Statut:
ppublish
Résumé
This review provides an in-depth exploration of portal hypertension (PH) and its implications in various surgical procedures. The prevalence of clinically significant PH is 50% to 60% in compensated cirrhosis and 100% in decompensated cirrhosis. The feasibility and safety of hepatic and nonhepatic surgical procedures in patients with PH has been shown. Adequate preoperative risk assessment and optimization of PH are integral parts of patient assessment. The occurrence of adverse outcomes after surgery has decreased over time in this specific population, due to the development of techniques and improved perioperative multidisciplinary care.
Identifiants
pubmed: 38945643
pii: S1089-3261(24)00037-0
doi: 10.1016/j.cld.2024.04.001
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
555-576Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure A. Berzigotti is a consultant to Boehringer-Inhelheim. G. Sapisochin is consultant to AstraZeneca, Integra, Novartis, Roche, and HepaRegeniX. He also received grants from Roche, Switzerland and Bayer, Germany.